A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 10/20/2018 |
| Start Date: | August 2012 |
| End Date: | March 2029 |
A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
The purpose of this study is to examine the long term safety of an experimental gene transfer
agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
Inclusion Criteria:
- Must have received a subretinal injection of RetinoStat
- Must have been enrolled in Protocol RS1/001/10
Exclusion Criteria:
- Did not receive RetinoStat® as part of the RS1/001/10 protocol
We found this trial at
3
sites
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
Click here to add this to my saved trials